Navigenics Names Jonathan Lord, MD to Serve as President and Chief Executive Officer

FOSTER CITY, Calif.--(Business Wire)--
Navigenics, a leading personal genomics testing company, announced today that
Jonathan "Jack" T. Lord, MD, has been appointed by the Board of Directors to
serve as President and Chief Executive Officer of the firm.

Dr. Lord brings to Navigenics a history and passion for combining robust medical
science with technological innovation to improve consumers` health and access to
quality care. Dr. Lord comes to Navigenics from Louisville, Kentucky-based
Humana, Inc., where as Chief Innovation Officer he was responsible for designing
new products and services to enable people to navigate the healthcare system and
support their health needs. Before Humana, Dr. Lord was president of Health
Dialog in Boston, where he helped pioneer e-enabled health care. He has also
served as chief operating officer of the American Hospital Association in
Washington, D.C. Previously, Dr. Lord was executive vice president of Anne
Arundel Medical Center in Annapolis, MD, and executive vice president of Sun
Health in Charlotte, NC.

"I am excited about the prospects of leading a company that will transform
healthcare. Navigenics` leadership in science, its exceptionally committed and
leading-edge investors, and strong management team make this the most exciting
opportunity of my career," said Dr. Lord. "Passion for advancing personalized
medicine defines Navigenics. I am very honored to have the privilege to lead
this company as we transform healthcare for the 21st century - an era of
healthcare we hope will be marked by a focus on prediction and prevention."

"When evaluating candidates for a new chief executive officer to take the helm
at Navigenics, we gave high marks to Jack`s demonstrated commitment to our core
values: innovating health care by using the latest scientific and technological
advances to help physicians and individuals prevent disease," said Dana G. Mead
Jr., partner at Kleiner Perkins Caufield & Byers and member of Navigenics` Board
of Directors. "Jack has a unique, 360-degree understanding of the healthcare
ecosystem and will no doubt help lead the entire genomics industry as genetic
science, clinical adoption and public policy evolve."

In addition to his operational leadership roles, Dr. Lord has solid board
experience. He has served on the board of directors at TheraSense, a developer
of personal clinical self-monitoring devices which was acquired by Abbott
Laboratories during Dr. Lord`s tenure. Dr. Lord also serves on the board of
Stericycle, a leader in healthcare infection control and compliance services,
and Dexcom, a developer of glucose monitoring systems.

His expertise is sought at the national level, as demonstrated by Dr. Lord`s
invitation by the Department of Health and Human Services to serve on the Center
for Disease Control and Prevention (CDC) Advisory Committee to the Director in
2008. The committee advises CDC leadership on key strategic issues in order to
assist the agency in fulfilling its vision of health protection and health
equity. He was also appointed as an advisory board member of the World Economic
Forum`s Global Agenda Council on Chronic Disease and Malnutrition.

"As a physician-researcher and hands on health futurist, Jack has become a
global leader in health care innovation, promotion and prevention," said Mike
McCallister, President and Chief Executive Officer of Humana. "For the past nine
years, his work as head of Humana`s Innovation Center has powerfully transformed
the company and the entire health benefits industry."

"Jack is a visionary who as both a physician and healthcare executive has been a
recognized leader in preventive medicine, consumer health and genetic science,"
said Donna Shalala, president of the University of Miami and former U.S.
Secretary of Health and Human Services.

Dr. Lord will assume his position on May 1, 2009.

ABOUT NAVIGENICS

Navigenics, Inc. is a privately held company based in Foster City, Calif. The
company was founded by David Agus, M.D. and Dietrich Stephan, Ph.D., with the
goal of improving health outcomes in individuals across the population.
Navigenics educates and empowers individuals and their physicians with knowledge
of their genetic predispositions, and then motivates them to act on the
information to prevent the onset of disease, achieve earlier diagnosis,
appropriately manage disease, or otherwise lessen its impact. Navigenics` lead
investors are Kleiner Perkins Caufield and Byers, Sequoia Capital and MDV-Mohr
Davidow Ventures. More information can be found at www.navigenics.com.

Feinstein Kean Healthcare
David Harvey, 415-677-2802
David.Harvey@fkhealth.com
or
Navigenics
Brenna Sweeney, 650-585-7523
bsweeney@navigenics.com

Copyright Business Wire 2009